Actinobac Biomed Receives Venture Capital Commitment
Tuesday, March 24, 2009 5:58:00 AM PDT | VentureDeal Staff
New Brunswick, New Jersey -- Biotechnology company Actinobac Biomed has received a $500,000 commitment, according to a company announcement.
Actinobac is developing a therapeutic agent "targeting white leukemic blood cells for the treatment of hematological malignancies, including leukemia, myeloma and lymphoma."
The Foundation Venture Capital Group made the capital commitment. The company did not disclose how it would use the funding proceeds.
Email Page | Print Page